Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, this FDA Warning Letter issued to Alkermes, Inc. on December 2, 2019 concerns drug product violations, though the specific nature of the violations cannot be determined as the subject line is unavailable. Alkermes is a pharmaceutical company subject to FDA oversight of its drug manufacturing and marketing practices. Without access to the full warning letter text, the precise regulatory violations and the specific issuing FDA office cannot be identified, though the letter indicates compliance concerns warranting formal FDA enforcement action.